Peter Marks, CBER (MDA USA via Twitter)

Pe­ter Marks on Covid-19 vac­cine ef­fi­ca­cy, EUAs and chal­lenge tri­als

A week af­ter the FDA is­sued guid­ance on vac­cines to pre­vent Covid-19, Pe­ter Marks, di­rec­tor of the Cen­ter for Bi­o­log­ics Eval­u­a­tion and Re­search, shed light on the rea­son­ing be­hind the agency’s 50% ef­fi­ca­cy thresh­old and where the agency stands on chal­lenge tri­als and emer­gency use au­tho­riza­tions.

Ef­fi­ca­cy and ap­proval

In its guid­ance, FDA said it ex­pect­ed spon­sors to demon­strate a vac­cine is at least 50% ef­fec­tive in a place­bo-con­trolled tri­al, with an ad­just­ed low­er bound of >30%.

Dur­ing a tele­con­fer­ence with the Al­liance for a Stronger FDA on Wednes­day, Marks ex­plained that the 50% fig­ure is based on what the agency could tol­er­ate for ef­fi­ca­cy. “Can we show you some cal­cu­la­tion of how we got there? No,” he said, not­ing that the agency does not typ­i­cal­ly set spe­cif­ic ef­fi­ca­cy tar­gets in its vac­cine guid­ance.

“If you go much low­er than 50% then the low­er bounds of things start to get to a place where vac­cines may have very lit­tle ef­fi­ca­cy,” Marks added. “On the oth­er hand, if we held that num­ber at 70% to 80% … we may not have a vac­cine un­til there’s herd im­mu­ni­ty that’s oc­curred nat­u­ral­ly.”

How­ev­er, Marks said that erad­i­cat­ing the virus will like­ly re­quire a more ef­fec­tive vac­cine. “We’re go­ing to need a vac­cine that’s prob­a­bly in the or­der of 70% ef­fec­tive and 70%, at least, of the pop­u­la­tion is go­ing to need to take it,” he said.

Based on those pa­ra­me­ters, Marks said that piv­otal tri­als for Covid-19 vac­cines will need to be large. “Large means tens of thou­sands of peo­ple, prob­a­bly … some­where be­tween ten to fif­teen thou­sand in­di­vid­u­als in each arm of a ran­dom­ized tri­al to get to the kind of pow­er that you need here.”

Marks could not com­ment on how quick­ly vac­cine could be avail­able but said, “We’re not go­ing to have one in ear­ly fall, it’s go­ing to take months.”

As stat­ed in the agency’s guid­ance, Marks stressed that ac­cel­er­at­ed ap­proval is not ap­pro­pri­ate un­til there are com­pelling sur­ro­gate end­points.

“Giv­en the cur­rent lack of da­ta that we have in­form­ing im­mune cor­re­lates of pro­tec­tion, we’re telling peo­ple that the clin­i­cal de­vel­op­ment pro­gram should pur­sue tra­di­tion­al ap­proval, based on di­rect ev­i­dence of vac­cine ef­fi­ca­cy,” Marks said. “Af­ter a few vac­cines come through the pipeline, we may un­der­stand what a good im­mune cor­re­late of pro­tec­tion is, but we don’t yet know that an­ti­bod­ies are the be-all-end-all of pro­tect­ing against COVID-19.”

Marks al­so ex­pand­ed on whether the agency would con­sid­er is­su­ing an emer­gency use au­tho­riza­tion for a Covid-19 vac­cine.

“We re­al­ly be­lieve that the most like­ly sit­u­a­tion in which an emer­gency use au­tho­riza­tion would be is­sued would be af­ter some in­ter­im analy­sis that shows vac­cine ef­fi­ca­cy and safe­ty, be­fore a for­mal sub­mis­sion is made to the FDA of a li­cen­sure ap­pli­ca­tion and FDA has had a chance to do its nor­mal re­view,” he said.

Chal­lenge tri­als

One of the more eye­brow-rais­ing as­pects of FDA’s guid­ance was a sec­tion dis­cussing the po­ten­tial for chal­lenge tri­als, or con­trol hu­man in­fec­tion mod­els, where­in vol­un­teers are in­ten­tion­al­ly ex­posed to a pathogen. In its guid­ance, FDA sug­gests that such tri­als could be en­ter­tained, “If it is no longer pos­si­ble to demon­strate vac­cine ef­fec­tive­ness by way of con­duct­ing clin­i­cal dis­ease end­point ef­fi­ca­cy stud­ies.”

“Why can’t we do that for COVID-19?” Marks asked. “Well, there are prob­a­bly a cou­ple rea­sons. One of which is that you don’t have some­thing that cures COVID-19 100% of the time or near 100% of the time.” Marks said there are oth­er is­sues that would need to be worked out be­fore such tri­als would be fea­si­ble, in­clud­ing im­prov­ing our un­der­stand­ing of the dis­ease and de­ter­min­ing which strain of the virus to use.

“This could be a way to­wards re­al­ly fa­cil­i­tat­ing get­ting an an­swer, if we had a res­cue treat­ment and if we knew more about the re­la­tion­ship be­tween car­riage and in­fec­tion, but right now it gives peo­ple some eth­i­cal heart­burn and sci­en­tif­i­cal­ly it’s com­pli­cat­ed,” Marks said.

That said, Marks said FDA would con­sid­er pro­pos­als for chal­lenge tri­als based on what was in the pro­to­col and the cir­cum­stances at the time. “It’s not a ‘no’, it’s a ‘we’ll see,’” he said.

Marks added that it might be more fea­si­ble to con­duct chal­lenge tri­als when there are more ef­fec­tive ther­a­peu­tics avail­able to treat the dis­ease. “If we have mon­o­clon­al an­ti­bod­ies that are re­al­ly good at shut­ting down the dis­ease, that could be a game chang­er.”

Safe­ty and qual­i­ty

Marks said that one of the things that “scares me more than any­thing else is that a third or half of Amer­i­cans are hes­i­tant about tak­ing a vac­cine [for COVID-19].” Marks stressed that part of FDA’s job is to as­sure that an even­tu­al vac­cine is safe and high qual­i­ty.

“For any of these vac­cines tar­get­ing SARS-CoV-2, im­por­tant things for us from the stand­point of our guid­ance… will be things like con­sis­ten­cy of man­u­fac­tur­ing, and the need for man­u­fac­tur­ing process­es and con­trols that have ap­pro­pri­ate steps in them, the need to have fa­cil­i­ties in­spect­ed to pro­duce vac­cines un­der good man­u­fac­tur­ing prac­tices, that’s im­por­tant be­cause we re­al­ly do need to make sure that these are go­ing to be high qual­i­ty prod­ucts that when we say they’re safe, they re­al­ly are,” Marks said.

For a look at all End­points News coro­n­avirus sto­ries, check out our spe­cial news chan­nel.


RAPS: First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

Im­ple­ment­ing re­silience in the clin­i­cal tri­al sup­ply chain

Since January 2020, the clinical trials ecosystem has quickly evolved to manage roadblocks impeding clinical trial integrity, and patient care and safety amid a global pandemic. Closed borders, reduced air traffic and delayed or canceled flights disrupted global distribution, revealing how flexible logistics and supply chains can secure the timely delivery of clinical drug products and therapies to sites and patients.

In fi­nal days at Mer­ck, Roger Perl­mut­ter bets big on a lit­tle-known Covid-19 treat­ment

Roger Perlmutter is spending his last days at Merck, well, spending.

Two weeks after snapping up the antibody-drug conjugate biotech VelosBio for $2.75 billion, Merck announced today that it had purchased OncoImmune and its experimental Covid-19 drug for $425 million. The drug, known as CD24Fc, appeared to reduce the risk of respiratory failure or death in severe Covid-19 patients by 50% in a 203-person Phase III trial, OncoImmune said in September.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.

Pascal Soriot (AP Images)

UP­DAT­ED: As­traZeneca, Ox­ford on the de­fen­sive as skep­tics dis­miss 70% av­er­age ef­fi­ca­cy for Covid-19 vac­cine

On the third straight Monday that the world wakes up to positive vaccine news, AstraZeneca and Oxford are declaring a new Phase III milestone in the fight against the pandemic. Not everyone is convinced they will play a big part, though.

With an average efficacy of 70%, the headline number struck analysts as less impressive than the 95% and 94.5% protection that Pfizer/BioNTech and Moderna have boasted in the past two weeks, respectively. But the British partners say they have several other bright spots going for their candidate. One of the two dosing regimens tested in Phase III showed a better profile, bringing efficacy up to 90%; the adenovirus vector-based vaccine requires minimal refrigeration, which may mean easier distribution; and AstraZeneca has pledged to sell it at a fraction of the price that the other two vaccine developers are charging.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.

Bob Nelsen (Photo by Michael Kovac/Getty Images)

Bob Nelsen rais­es $800M and re­cruits a star-stud­ded board to build the 'Fox­con­n' of biotech

Bob Nelsen spent his pandemic spring in his Seattle home, talking on the phone with Luciana Borio, the scientist who used to run pandemic preparedness on the National Security Council, and fuming about the dire state of American manufacturing.

Companies were rushing to develop vaccines and antibodies for the new virus, but even if they succeeded, there was no immediate supply chain or infrastructure to mass-produce them in a way that could make a dent in the outbreak.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.

Leonard Schleifer, Regeneron CEO (Andrew Harnik/AP)

Trail­ing Eli Lil­ly by 12 days, Re­gen­eron gets the FDA OK for their Covid-19 an­ti­body cock­tail

A month and a half after becoming the experimental treatment of choice for a newly diagnosed president, Regeneron’s antibody cocktail has received emergency use authorization from the FDA. It will be used to treat non-hospitalized Covid-19 patients who are at high-risk of progressing.

Although the Rgeneron drug is not the first antibody treatment authorized by the FDA, the news comes as a significant milestone for a company and a treatment scientists have watched closely since the outbreak began.

Am­gen sev­ers 14-year Cy­to­ki­net­ics part­ner­ship, bail­ing on ome­cam­tiv af­ter mixed PhI­II re­sults

Amgen is shrugging off a 14-year development alliance and the tens of millions of dollars spent to develop a new heart drug at Cytokinetics after a Phase III trial turned up weak data — leaving Cytokinetics to soldier on alone.

Omecamtiv mecarbil technically worked, meeting the primary composite endpoint in the Phase III GALACTIC-HF study. But it missed a key secondary endpoint, which analysts had been following as a key marker for success — reduction of cardiovascular (CV) death. While Cytokinetics celebrated the results, its stock tanked 43% upon the news, and analysts warned of an uncertain path ahead. Now, Amgen wants out.

News brief­ing: Ab­b­Vie part­ner Teneo­bio ex­pands tech li­cense with CAR-T play­er Po­sei­da; Ar­genx buys PRV from Bay­er for $98M

Teneobio may be best known for its pact with AbbVie and Gilead, but before its big break the bispecific player had licensed its antibodies for a different use: as binders in CAR-T therapies being developed by Poseida.

Now, the biotechs are expanding their partnership, with Poseida exercising four options to deploy Teneobio’s heavy chain only domain antibodies commercially.

The commercial licensing fees remained under wraps, but Teneobio is eligible for $250 million in milestones for these CAR-Ts against undisclosed targets.

Ramy Farid, Schrödinger CEO (Schrödinger)

Bris­tol My­ers fronts new Schrödinger al­liance with $55M up­front, ex­pand­ing pre­ci­sion on­col­o­gy pro­file

Bristol Myers Squibb has a new R&D partner, one to which they’re paying a pretty penny to use their discovery platform.

The pharma company is doling out $55 million upfront to Schrödinger $SDGR to work on up to five small molecules, with the potential for $2.7 billion in milestone payments. Schrödinger’s initial targets include HIF-2 alpha and SOS1/KRAS for a type of kidney cancer and KRAS-driven cancers, respectively.

Peter Thiel (Riccardo Savi/Sipa via AP Images)

Tech bil­lion­aire Pe­ter Thiel backs a lead­ing psy­che­del­ic drug de­vel­op­er

Right on the heels of investing in antibody drug developer AbCellera, Facebook billionaire Peter Thiel has jumped into a syndicate putting up $125 million for a company with a portfolio of psychedelic drugs in the clinic for mental health.

The C round — which includes a $32 million conversion of notes to equity — will fuel the development programs at ATAI Life Sciences, a Berlin-based biotech that has assembled a portfolio of companies with psychedelic and non-psychedilc approaches to depression, anxiety and addiction.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.